These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Shimizu Y; Tada Y; Yamauchi M; Okamoto T; Suzuki H; Ito N; Fukumoto S; Sugimoto T; Fujita T Bone; 2009 Oct; 45(4):814-6. PubMed ID: 19555782 [TBL] [Abstract][Full Text] [Related]
47. A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet. Raeder H; Shaw N; Netelenbos C; Bjerknes R Eur J Endocrinol; 2008 Dec; 159 Suppl 1():S101-5. PubMed ID: 18775977 [TBL] [Abstract][Full Text] [Related]
48. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endo I; Fukumoto S; Ozono K; Namba N; Inoue D; Okazaki R; Yamauchi M; Sugimoto T; Minagawa M; Michigami T; Nagai M; Matsumoto T Endocr J; 2015; 62(9):811-6. PubMed ID: 26135520 [TBL] [Abstract][Full Text] [Related]
49. Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol. Harrell RM; Lyles KW; Harrelson JM; Friedman NE; Drezner MK J Clin Invest; 1985 Jun; 75(6):1858-68. PubMed ID: 3839245 [TBL] [Abstract][Full Text] [Related]
51. Hypophosphatemia: an evidence-based problem-solving approach to clinical cases. Assadi F Iran J Kidney Dis; 2010 Jul; 4(3):195-201. PubMed ID: 20622306 [TBL] [Abstract][Full Text] [Related]
52. Parenteral iron therapy and phosphorus homeostasis: A review. Kalantar-Zadeh K; Ganz T; Trumbo H; Seid MH; Goodnough LT; Levine MA Am J Hematol; 2021 May; 96(5):606-616. PubMed ID: 33471363 [TBL] [Abstract][Full Text] [Related]
53. Emerging topics in pediatric bone and mineral disorders 2008. McKay CP; Portale A Semin Nephrol; 2009 Jul; 29(4):370-8. PubMed ID: 19615558 [TBL] [Abstract][Full Text] [Related]
54. Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis. Goldsweig BK; Carpenter TO Curr Osteoporos Rep; 2015 Apr; 13(2):88-97. PubMed ID: 25620749 [TBL] [Abstract][Full Text] [Related]
55. Evaluation of the parathyroid function in six patients with hypophosphatemic osteomalacia, including a case of tertiary hyperparathyroidism developing during combined oral phosphate and vitamin D therapy. Jeon HJ; Kwon SH; Kim SW; Shin CS; Park KS; Kim SY; Cho BY; Lee HK Horm Res; 2003; 60(3):127-33. PubMed ID: 12931040 [TBL] [Abstract][Full Text] [Related]
56. Hypophosphatemic osteomalacia: an unusual clinical presentation of multiple myeloma. Reyskens M; Sleurs K; Verresen L; Janssen M; van den Bergh J; Geusens P Osteoporos Int; 2015 Jul; 26(7):2039-42. PubMed ID: 25906239 [TBL] [Abstract][Full Text] [Related]
57. Familial adult onset X-linked hypophosphataemic osteomalacia (report of a family; clinical and experimental studies). Radó JP; Haris A; Szebenyi B Acta Physiol Hung; 1997-1998; 85(3):199-214. PubMed ID: 10101535 [TBL] [Abstract][Full Text] [Related]
59. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
60. Somatic mutations of the MEN1 gene and microsatellite instability in a case of tertiary hyperparathyroidism occurring during high phosphate therapy for acquired, hypophosphatemic osteomalacia. Sato K; Obara T; Yamazaki K; Kanbe M; Nakajima K; Yamada A; Yanagisawa T; Kato Y; Nishikawa T; Takano K J Clin Endocrinol Metab; 2001 Nov; 86(11):5564-71. PubMed ID: 11701736 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]